| scholarly article | Q13442814 |
| P2093 | author name string | Jie Pan | |
| Qi Bao | |||
| Georg Enders | |||
| P2860 | cites work | mTOR signaling in growth control and disease | Q24634174 |
| A simple practice guide for dose conversion between animals and human | Q26750843 | ||
| Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism | Q27678762 | ||
| Tropomyosin receptor kinase: a novel target in screened neuroendocrine tumors | Q52644121 | ||
| The immune response to sporadic colorectal cancer in a novel mouse model | Q52901776 | ||
| The role of GSK3 and its reversal with GSK3 antagonism in everolimus resistance | Q56967510 | ||
| Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study | Q64091221 | ||
| A transgenic mouse line that develops early-onset invasive gastric carcinoma provides a model for carcinoembryonic antigen-targeted tumor therapy | Q73863852 | ||
| Geographic and demographic features of neuroendocrine tumors in the United States of America: A population-based study | Q91243423 | ||
| The promise and peril of targeting cell metabolism for cancer therapy | Q91536768 | ||
| The Metabolic Landscape of Lung Cancer: New Insights in a Disturbed Glucose Metabolism | Q91711246 | ||
| ONCOGENE PANEL SEQUENCING ANALYSIS IDENTIFIES CANDIDATE ACTIONABLE GENES IN ADVANCED WELL-DIFFERENTIATED GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS | Q92327792 | ||
| Two well-differentiated pancreatic neuroendocrine tumor mouse models | Q92502812 | ||
| A genetic origin for acid-base imbalance triggers the mitochondrial damage that explains the autoimmune response and drives to gastric neuroendocrine tumours | Q93093179 | ||
| Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, pha | Q38609552 | ||
| EPIDEMIOLOGY OF GASTROINTESTINAL NEUROENDOCRINE TUMORS IN A US COMMERCIALLY INSURED POPULATION. | Q38658206 | ||
| Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. | Q38679359 | ||
| Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors | Q38786234 | ||
| Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms | Q38858270 | ||
| Combined therapy with RAD001 e BEZ235 overcomes resistance of PET immortalized cell lines to mTOR inhibition | Q38975178 | ||
| Tenascin-C downregulates wnt inhibitor dickkopf-1, promoting tumorigenesis in a neuroendocrine tumor model | Q39076874 | ||
| mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids. | Q39154831 | ||
| Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease | Q39720433 | ||
| Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors | Q39981784 | ||
| Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes | Q43470250 | ||
| Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies | Q45067792 | ||
| Genomic landscape of pancreatic neuroendocrine tumours: The International Cancer Genome Consortium | Q48520101 | ||
| Prkar1a gene knockout in the pancreas leads to neuroendocrine tumorigenesis | Q50303251 | ||
| Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers | Q27851457 | ||
| Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade | Q27853295 | ||
| Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia | Q28143642 | ||
| Gastroenteropancreatic neuroendocrine tumours | Q28263732 | ||
| DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors | Q28303693 | ||
| Preclincial testing of Sorafenib and RAD001 in the Nfflox/flox;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging | Q28305337 | ||
| Tumor cell metabolism: cancer's Achilles' heel | Q29619809 | ||
| A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. | Q30984959 | ||
| A transgenic mouse model of metastatic carcinoma involving transdifferentiation of a gastric epithelial lineage progenitor to a neuroendocrine phenotype | Q33201186 | ||
| Characterization of gastric adenocarcinoma cell lines established from CEA424/SV40 T antigen-transgenic mice with or without a human CEA transgene | Q33236456 | ||
| A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells | Q33585069 | ||
| Biologics in gastrointestinal and pancreatic neuroendocrine tumors | Q33895557 | ||
| Expression of a neuroendocrine gene signature in gastric tumor cells from CEA 424-SV40 large T antigen-transgenic mice depends on SV40 large T antigen | Q34130710 | ||
| Aging, Cellular Senescence, and Cancer | Q34199776 | ||
| Everolimus for advanced pancreatic neuroendocrine tumors. | Q34399809 | ||
| Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET. | Q34499075 | ||
| Regulation of Senescence in Cancer and Aging | Q34665706 | ||
| Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway | Q34887795 | ||
| Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging | Q34966603 | ||
| Reversal of human cellular senescence: roles of the p53 and p16 pathways | Q35561999 | ||
| Cellular senescence in cancer treatment: friend or foe? | Q35628579 | ||
| Combined inhibition of MEK and mTOR has a synergic effect on angiosarcoma tumorgrafts | Q35798540 | ||
| AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy. | Q35886886 | ||
| Cellular senescence and cancer chemotherapy resistance | Q35947022 | ||
| Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer | Q36357373 | ||
| Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer | Q36788057 | ||
| Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation | Q36971030 | ||
| One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States | Q37195528 | ||
| A knockin mouse model for human ATP4aR703C mutation identified in familial gastric neuroendocrine tumors recapitulates the premalignant condition of the human disease and suggests new therapeutic strategies | Q37305896 | ||
| Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma. | Q37462300 | ||
| mTOR signaling and drug development in cancer | Q37710367 | ||
| The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors | Q37832970 | ||
| Translation of Molecular Pathways into Clinical Trials of Neuroendocrine Tumors | Q38003074 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | neuroendocrine tumor | Q1981276 |
| P304 | page(s) | 546 | |
| P577 | publication date | 2020-04-21 | |
| P1433 | published in | Frontiers in Oncology | Q26839986 |
| P1476 | title | The Altered Metabolic Molecular Signatures Contribute to the RAD001 Resistance in Gastric Neuroendocrine Tumor | |
| P478 | volume | 10 |
Search more.